MINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.624
EU - Europa 9.880
AS - Asia 2.123
AF - Africa 21
SA - Sud America 14
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 26.676
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.566
PL - Polonia 3.811
IE - Irlanda 1.830
IT - Italia 1.407
SE - Svezia 1.071
HK - Hong Kong 961
UA - Ucraina 432
DE - Germania 425
CN - Cina 423
FI - Finlandia 256
JO - Giordania 236
GB - Regno Unito 199
SG - Singapore 194
RU - Federazione Russa 144
IN - India 84
VN - Vietnam 81
CH - Svizzera 79
TR - Turchia 74
FR - Francia 63
CA - Canada 49
KR - Corea 48
BE - Belgio 42
ES - Italia 42
AT - Austria 39
NL - Olanda 17
SC - Seychelles 15
BR - Brasile 10
NZ - Nuova Zelanda 9
MX - Messico 7
DK - Danimarca 5
IR - Iran 5
EU - Europa 4
GR - Grecia 4
CZ - Repubblica Ceca 3
MU - Mauritius 3
PH - Filippine 3
PK - Pakistan 3
AL - Albania 2
BT - Bhutan 2
MK - Macedonia 2
PE - Perù 2
PR - Porto Rico 2
RO - Romania 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
CO - Colombia 1
DZ - Algeria 1
HR - Croazia 1
ID - Indonesia 1
IL - Israele 1
JP - Giappone 1
MD - Moldavia 1
NP - Nepal 1
PT - Portogallo 1
SA - Arabia Saudita 1
TW - Taiwan 1
Totale 26.676
Salva come PNG Salva come JPEG
Città #
Warsaw 3.796
Fairfield 2.104
Dublin 1.822
Chandler 1.603
Ashburn 1.167
Woodbridge 970
Cambridge 867
Seattle 860
Houston 786
Wilmington 755
Jacksonville 677
Hong Kong 526
Ann Arbor 452
Princeton 382
Altamura 366
Lawrence 357
Florence 286
Boston 273
Boardman 205
Beijing 190
Buffalo 175
Medford 163
Shanghai 147
San Diego 126
Singapore 110
Moscow 95
Bremen 88
New York 82
West Jordan 78
Bern 75
Falls Church 74
Norwalk 61
Dearborn 60
Kent 60
Dong Ket 56
Izmir 50
Pune 49
Hillsboro 46
Brussels 39
Vienna 39
Toronto 38
Barcelona 35
Milan 34
Rome 34
Auburn Hills 32
Los Angeles 29
Phoenix 28
Andover 25
London 24
Verona 19
Helsinki 18
Frankfurt Am Main 17
Redmond 17
Washington 17
Redwood City 15
Chennai 14
Laurel 13
Palermo 13
Catania 11
Council Bluffs 9
Philadelphia 9
Prato 9
San Mateo 9
Tappahannock 9
Bari 8
Giugliano in Campania 8
Guadalajara 8
Guangzhou 8
Kilburn 8
Paris 8
Seongnam 8
Seoul 8
Bologna 7
Auckland 6
Kunming 6
Montréal 6
Padova 6
Prescot 6
São Paulo 6
Turin 6
Arezzo 5
Duncan 5
Fuzhou 5
Genoa 5
Livorno 5
Modena 5
Naples 5
Sesto Fiorentino 5
Trumbull 5
Clifton 4
Fiesole 4
Grottammare 4
Hanoi 4
Ladispoli 4
Lastra a Signa 4
Menlo Park 4
Monte San Giusto 4
Naaldwijk 4
New Bedfont 4
Perugia 4
Totale 20.797
Salva come PNG Salva come JPEG
Nome #
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 249
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 245
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 245
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 243
Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor 242
Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds 240
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 240
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. 238
Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy 238
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 237
Emerging drugs in refractory colorectal cancer 229
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 227
The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. 225
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 224
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 223
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 220
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 219
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 217
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 212
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 207
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 202
Druggable Targets in Pancreatic Adenocarcinoma 198
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 197
Natural compounds for cancer treatment and prevention 193
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 192
Mutations of the APC gene in human sporadic colorectal cancers. 189
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 170
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 165
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 161
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 155
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 153
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 130
Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters 125
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 117
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm) 116
Pharmacogenetics: Implementing personalized medicine 116
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 111
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 110
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 109
Cellular pharmacology of gemcitabine. 109
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 107
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 107
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 105
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 104
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 104
New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR) 103
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 103
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 101
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. 101
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 101
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 101
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. 101
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. 98
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 95
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis 95
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 93
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study 92
Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation. 91
Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues. 91
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 90
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. 89
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 89
6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial 89
LIPOSOMES LOADED WITH BERBERINE HYDROCHLORIDE: DEVELOPMENT, OPTIMISATION AND IN VITRO CITOTOXICITY 87
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights 87
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program 87
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 86
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 86
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I. 86
Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci. 85
Pharmacological strategies for overcoming multidrug resistance. 84
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. 84
Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14) 84
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 83
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 82
Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. 82
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 82
Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands 81
ENHANCEMENT OF THE ANTITUMOR EFFECTS OF 5-FLUOROURACIL BY FOLINIC ACID. 80
Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. 80
Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial 80
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 79
2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial 79
Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate. 79
Clinical pharmacokinetics of depot leuprorelin. 78
Long-term azithromycin in cystic fibrosis: another possible mechanism of action? 78
Synthesis of new pyrazolo[5,1-c][1,2,4]benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions. 78
Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma. 78
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. 78
Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides. 77
Antimicrobial prophylaxis in orthopaedic surgery: the role of teicoplanin. 77
Prognostic factors in primary and iterative surgery of colorectal liver metastases 77
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 77
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 77
Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum 76
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials 76
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 76
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. 76
Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial. 75
Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. 75
Totale 12.860
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.812
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.812
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.832 434 525 136 459 687 715 613 735 558 357 483 130
2020/20213.763 303 357 229 423 198 384 193 288 349 525 219 295
2021/20222.368 70 224 104 99 78 160 85 212 144 102 403 687
2022/20237.370 607 1.087 244 652 631 1.473 976 451 837 51 174 187
2023/20243.071 137 286 537 118 195 449 174 664 67 185 137 122
2024/2025212 212 0 0 0 0 0 0 0 0 0 0 0
Totale 27.263